

modafinil, oral (PROVIGIL)
PROVIGIL (modafinil, oral)

Diagnosis Considered for Coverage:

- Improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder

Coverage Criteria:

- 1. For generic armodafinil and diagnosis narcolepsy:**
 - Positive polysomnography (sleep study) for narcolepsy, **and**
 - Dose does not exceed 400 mg per day
- 2. For generic armodafinil and diagnosis obstructive sleep apnea:**
 - Sleep study confirms OSAHS OR patient is currently using CPAP or BiPAP therapy, **and**
 - Patient has hypersomnolence score at least 10 on the Epworth Sleepiness Scale, **and**
 - Dose does not exceed 400 mg per day, **and**
 - One of the following:
 - Patient is currently on CPAP AND armodafinil will be added to CPAP therapy, **or**
 - Patient is intolerant to CPAP and is using one of the following therapies for OSA: BiPAP, oral appliances AND armodafinil will be added, **or**
 - Patient has undergone a previous surgical procedure for OSA (uvulopalatopharyngoplasty, maxillomandibular advancement, or radiofrequency ablation of throat tissue).
- 3. For generic armodafinil and diagnosis shift work disorder:**
 - Dose does not exceed 400 mg per day, **and**
 - One of the following shift work schedule interrupts normal circadian sleep pattern:
 - Night shift worker with hours of 11pm-7am, **or**
 - Early morning shift worker with starting hours between 4am -7am, **or**
 - Rotating shift worker where scheduling changes adversely affect normal circadian sleep pattern.
- 4. For brand-name Provigil:**
 - Meets above coverage criteria for generic, **and**
 - Allergic or intolerable side effect to the generic formulation

Coverage Duration: Length of benefit

Effective: 2/04/2020